Vyome Holdings, Inc. (HIND) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Analysis Summary
Vyome Holdings, Inc. reported revenue of $319714 in the most recent fiscal year, growing at a 5-year CAGR of -51.0%.
Trailing-twelve-month margins: gross margin 46.5%, operating margin -32.5%, net margin -87.2%.
At the current price of $1.96, HIND has negative trailing earnings (P/E not meaningful) and an ROE of -254.62%. Market capitalisation stands at $14M.
Balance sheet quality for HIND: current ratio of 2.0, net cash position of $5.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.96 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.32 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -254.62% |
| Return on Invested Capital | -57.53% |
| Return on Assets | -123.23% |
| Gross Margin | 46.50% |
| Operating Margin | -3250.25% |
| Net Margin | -8716.77% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.37 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -18.08 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HIND | Vyome Holdings, Inc. | $14M | 2.32 | -254.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price Performance
| 1 month | -15.52% |
| 3 months | -9.68% |
| Year-to-date | -43.02% |
| 1 year | -70.35% |
| 3 years | -99.95% |
52-Week Range
| 52-week High | $9.56 |
| 52-week Low | $1.75 |
| Avg Volume (90d) | 18K |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks